FANJ
AERI

Financial Architects (New Jersey)’s Aerie Pharmaceuticals AERI Stock Holding History

Financial Architects (New Jersey)’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-400
Closed -$25K – 1542
2018
Q3 		$25K Buy
+400
New +$25.7K ﹤0.01% 868

Other funds holding AERI

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Financial Architects (New Jersey)'s AERI Position: Q4 2018 in Review

Financial Architects (New Jersey) sold out of Aerie Pharmaceuticals (AERI) in Q4 2018, closing a stake of 400 shares — an estimated $25K sold.

Financial Architects (New Jersey) first reported a position in AERI in Q3 2018 and held it in 1 quarter. The position peaked at $25K in Q3 2018. 160 funds tracked by Wall St. Rank hold AERI as of Q4 2018.

  • Financial Architects (New Jersey) reported no remaining Aerie Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Financial Architects (New Jersey) sold 400 Aerie Pharmaceuticals shares in Q4 2018, an estimated $25K.
  • Financial Architects (New Jersey) first reported a position in Aerie Pharmaceuticals in Q3 2018 and held it in 1 quarter.
  • Financial Architects (New Jersey)'s Aerie Pharmaceuticals position peaked at $25K in Q3 2018.
  • 160 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2018.

Based on Financial Architects (New Jersey)'s 13F filing for Q4 2018, filed 1 Feb 2019.